Keywords : therapeutics, Therapy
Summary Cornerstone Therapeutics Inc.(Cornerstone), formerly known as Critical Therapeutics, Inc., is a specialty pharmaceutical company. It acquires, develops and markets proprietary products for the hospital, niche respiratory and related specialty markets. The company's product portfolio comprises, Cardene I.V., Curosurf, Zyflo, Bethkis and HP/CP ER suspension. Cornerstone's product pipeline includes, Retavase and Lixar. It offer...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
Summary
Cornerstone Therapeutics Inc.(Cornerstone), formerly known as Critical Therapeutics, Inc., is a specialty pharmaceutical company. It acquires, develops and markets proprietary products for the hospital, niche respiratory and related specialty markets. The company's product portfolio comprises, Cardene I.V., Curosurf, Zyflo, Bethkis and HP/CP ER suspension. Cornerstone's product pipeline includes, Retavase and Lixar. It offers these products to retail pharmacy chains, wholesalers, group purchasing organizations, hospital systems and specialty pharmacies. Cornerstone is headquartered at Cary, North Carolina, the US.
The company plans to expand its product portfolio. This intent is visible as Cornerstone entered into an agreement with Chiesi Farmaceutici S.p.A. to acquire the US rights to commercialize BETHKIS, a tobramycin inhalation solution indicated to manage cystic fibrosis patients with pseudomonas aeruginosa.
Cornerstone Therapeutics Inc. (CRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Therapy Industry in North America
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 5
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare Deals By Type, 2007 to YTD 2013 6
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2007 to YTD 2013 7
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2007 to YTD 2013 8
Cornerstone Therapeutics Inc., Medical Devices Deals, 2007 to YTD 2013 9
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals Summary, 2007 to YTD 2013 10
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Cornerstone Therapeutics Reacquires HMGB1 Protein Technology Platform From MedImmune 12
Cornerstone Therapeutics Acquires Antibiotic Factive From Oscient Pharma 13
EKR Therapeutics Acquires Rights To Cardiovascular Products From PDL BioPharma 14
Venture Financing 16
EKR Therapeutics Secures $50 Million In Series D Financing 16
EKR Therapeutics Secures $13 Million In Series C Financing 18
Partnerships 20
ProStrakan Enters Into Co-Marketing Agreement With EKR Therapeutics 20
Cornerstone Enters Into Co-Development Agreement With Lupin 21
Meiji Seika Enters Into An Agreement With Cornerstone Biopharma 22
Biogen Idec Enters Into Agreement With Cardiokine 23
Merger 25
Critical Therapeutics Merges With Cornerstone BioPharma 25
Licensing Agreements 27
Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 27
Cornerstone Therapeutics Enters Into Licensing Agreement With Targacept 29
Cornerstone Therapeutics Enters Into Licensing Agreement With The Cough Company 31
Pacira Pharma Amends Licensing Agreement With EKR Therapeutics For DepoDur 32
Cornerstone BioPharma Enters Into Licensing Agreement With Neos Therapeutics 33
EKR Therapeutics Enters Into Licensing Agreement With Pacira Pharma For DepoDur 34
Equity Offering 35
Cornerstone Therapeutics Files Registration Statement For Public Offering Of $95 Million 35
Asset Transactions 37
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 37
Acquisition 38
Chieisi To Acquire Remaining 35% Stake In Cornerstone Therapeutics 38
Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To $150 Million 40
Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 43
Cornerstone Therapeutics Inc. - Key Competitors 45
Key Employees 46
Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
List of Tables
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Key Facts, 2011 1
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 1
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2007 to YTD 2013 1
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2007 to YTD 2013 1
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 5
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare Deals By Type, 2007 to YTD 2013 6
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2007 to YTD 2013 7
Cornerstone Therapeutics Inc., Deals By Therapy Area, 2007 to YTD 2013 8
Cornerstone Therapeutics Inc., Medical Devices Deals, 2007 to YTD 2013 9
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals Summary, 2007 to YTD 2013 10
Cornerstone Therapeutics Reacquires HMGB1 Protein Technology Platform From MedImmune 12
Cornerstone Therapeutics Acquires Antibiotic Factive From Oscient Pharma 13
EKR Therapeutics Acquires Rights To Cardiovascular Products From PDL BioPharma 14
EKR Therapeutics Secures $50 Million In Series D Financing 16
EKR Therapeutics Secures $13 Million In Series C Financing 18
ProStrakan Enters Into Co-Marketing Agreement With EKR Therapeutics 20
Cornerstone Enters Into Co-Development Agreement With Lupin 21
Meiji Seika Enters Into An Agreement With Cornerstone Biopharma 22
Biogen Idec Enters Into Agreement With Cardiokine 23
Critical Therapeutics Merges With Cornerstone BioPharma 25
Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 27
Cornerstone Therapeutics Enters Into Licensing Agreement With Targacept 29
Cornerstone Therapeutics Enters Into Licensing Agreement With The Cough Company 31
Pacira Pharma Amends Licensing Agreement With EKR Therapeutics For DepoDur 32
Cornerstone BioPharma Enters Into Licensing Agreement With Neos Therapeutics 33
EKR Therapeutics Enters Into Licensing Agreement With Pacira Pharma For DepoDur 34
Cornerstone Therapeutics Files Registration Statement For Public Offering Of $95 Million 35
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 37
Chieisi To Acquire Remaining 35% Stake In Cornerstone Therapeutics 38
Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To $150 Million 40
Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 43
Cornerstone Therapeutics Inc., Key Competitors 45
Cornerstone Therapeutics Inc., Key Employees 46
Cornerstone Therapeutics Inc., Subsidiaries 47
List of Figures
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013 1
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 5
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013 6
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2007 to YTD 2013 7
Cornerstone Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2007 to YTD 2013 8
Cornerstone Therapeutics Inc., Medical Devices Deals, 2007 to YTD 2013 9
